Cessatech A/S (NGM:CESSA)

Market Cap	428.30M +76.8%
Revenue (ttm)	8.29M +130.0%
Net Income	-15.80M
EPS	-0.87
Shares Out	18.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,860
Average Volume	25,459
Open	16.78
Previous Close	16.26
Day's Range	15.80 - 17.00
52-Week Range	6.00 - 26.00
Beta	0.65
RSI	41.91
Earnings Date	Feb 27, 2026

About Cessatech

Cessatech A/S, a pivotal-stage pediatric biotech company, develops specialty hospital medicines for children in Denmark. Its lead candidate product is CT001, a fixed-dose nasal spray for treating acute pain in children. The company also develops CT002, a non-invasive intranasal sedation for children undergoing medical procedures in Phase 2 clinical trials; and CT003, a topical anesthetic in pre-clinical development. Cessatech A/S was incorporated in 2020 and is based in Copenhagen, Denmark.

• Industry: Pharmaceutical Preparations
• Founded: 2020
• Employees: 3
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: CESSA

Financial Performance

In 2025, Cessatech's revenue was 5.72 million, an increase of 130.01% compared to the previous year's 2.49 million. Losses were -10.90 million, -25.67% less than in 2024.

Financial numbers in DKK